The Helicobacter pylori Genome Project: insights into H. pylori population structure from analysis of a worldwide collection of complete genomes
- PMID: 38081806
- PMCID: PMC10713588
- DOI: 10.1038/s41467-023-43562-y
The Helicobacter pylori Genome Project: insights into H. pylori population structure from analysis of a worldwide collection of complete genomes
Abstract
Helicobacter pylori, a dominant member of the gastric microbiota, shares co-evolutionary history with humans. This has led to the development of genetically distinct H. pylori subpopulations associated with the geographic origin of the host and with differential gastric disease risk. Here, we provide insights into H. pylori population structure as a part of the Helicobacter pylori Genome Project (HpGP), a multi-disciplinary initiative aimed at elucidating H. pylori pathogenesis and identifying new therapeutic targets. We collected 1011 well-characterized clinical strains from 50 countries and generated high-quality genome sequences. We analysed core genome diversity and population structure of the HpGP dataset and 255 worldwide reference genomes to outline the ancestral contribution to Eurasian, African, and American populations. We found evidence of substantial contribution of population hpNorthAsia and subpopulation hspUral in Northern European H. pylori. The genomes of H. pylori isolated from northern and southern Indigenous Americans differed in that bacteria isolated in northern Indigenous communities were more similar to North Asian H. pylori while the southern had higher relatedness to hpEastAsia. Notably, we also found a highly clonal yet geographically dispersed North American subpopulation, which is negative for the cag pathogenicity island, and present in 7% of sequenced US genomes. We expect the HpGP dataset and the corresponding strains to become a major asset for H. pylori genomics.
© 2023. The Author(s).
Conflict of interest statement
J.P.G. has served as a speaker, consultant, and advisory member for or has received research funding from Mayoly, Allergan, Diasorin, Gebro Pharma, and Richen. E.B.-M. has served as a speaker and consultant for Janssen, Chiesi, Kern and Takeda. R.M.F., J.C.M., and C.F. own patent WO/2018/169423 on microbiome markers for gastric cancer, and R.J.R. works for New England Biolabs, a company that sells research reagents, including restriction enzymes and DNA methyltransferases, to the scientific community. The remaining authors declare no competing interests.
Figures





References
Publication types
MeSH terms
Grants and funding
- R01 CA281732/CA/NCI NIH HHS/United States
- P30 DK058404/DK/NIDDK NIH HHS/United States
- R03 CA167773/CA/NCI NIH HHS/United States
- K22 CA226395/CA/NCI NIH HHS/United States
- P01 CA116087/CA/NCI NIH HHS/United States
- R01 DK062813/DK/NIDDK NIH HHS/United States
- K07 CA125588/CA/NCI NIH HHS/United States
- P01 CA028842/CA/NCI NIH HHS/United States
- K08 CA252635/CA/NCI NIH HHS/United States
- R01 CA077955/CA/NCI NIH HHS/United States
- R01 CA190612/CA/NCI NIH HHS/United States
- U54 GM133807/GM/NIGMS NIH HHS/United States
- P30 CA068485/CA/NCI NIH HHS/United States
- I01 CX002171/CX/CSRD VA/United States
- R01 ES010178/ES/NIEHS NIH HHS/United States
- R01 DK058587/DK/NIDDK NIH HHS/United States